New stroke drug LT3001 passes first safety check in healthy people
NCT ID NCT04809818
First seen Dec 26, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This early-stage study tested the safety of a new drug called LT3001, which is being developed for acute ischemic stroke. It involved 65 healthy adults to see how the drug behaves in the body and whether it interacts safely with common medications like aspirin and blood thinners. The goal was to gather safety information, not to treat stroke patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lumosa Phase 1 Unit
Cypress, California, 90630, United States
Conditions
Explore the condition pages connected to this study.